A Multi-center, Open Label, Single Arm, Multiple Dose Study to Assess the Pharmacokinetics of RO5072759 in Chinese Patients With CD20+ Malignant Disease.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Pharmacokinetics: Serum concentration of RO5072759 (GA101)
Predose, Cycle 1, Day 1, 8, 15; Cycles 2-8; Follow up
No
Clinical Trials
Study Director
Hoffmann-La Roche
China: Food and Drug Administration
YP25623
NCT01680991
September 2012
December 2014
Name | Location |
---|